Joseph's mailing address filed with the SEC is 45 MOULTON STREET, , CAMBRIDGE, MA, 02138.
Over the last 24 years, insiders at Curis Inc have traded over $10,321,234 worth of Curis Inc stock and bought 10,678,594 units worth $25,596,192 . The most active insiders traders include Partners L P/Ilbiotechnolog..., Discovery Technologies Ltd ..., and James R Mcnab. On average, Curis Inc executives and independent directors trade stock every 62 days with the average trade being worth of $811,553. The most recent stock trade was executed by James E Dentzer on 27 January 2022, trading 5,500 units of CRIS stock currently worth $17,160.
curis is a publicly-traded biotechnology company (nasdaq: cris) focused on the development and commercialization of innovative drug candidates for the treatment of human cancers. curis’s pipeline of drug candidates includes cudc-907, which is currently being investigating in clinical trials in patients with relapsed or refractory diffuse large b-cell lymphoma with alterations in the myc oncogene. curis is also engaged in a broad collaboration with aurigene in the areas of immuno-oncology and precision oncology. as part of this collaboration, curis has exclusive licenses to oral small molecule antagonists of the pd1 and vista pathways, including pdl1/vista antagonist ca-170, and oral small molecule antagonists of the pd1 and tim3 pathways, including pdl1/tim3 antagonist ca-327, as well as to molecules designed to inhibit the irak4 kinase, including ca-4948. ca-170 is currently undergoing testing in a phase 1 trial in patients with advanced solid tumors and lymphomas. ca-4948 is currentl
Curis Inc executives and other stock owners filed with the SEC include: